- Home
- CSTL vs AMRK Comparison
CSTL vs AMRK Comparison
Compare CSTL & AMRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- AMRK
- Stock Information
- Founded
- CSTL 2007
- AMRK 1965
- Country
- CSTL United States
- AMRK United States
- Employees
- CSTL N/A
- AMRK N/A
- Industry
- CSTL Medical Specialities
- AMRK Other Specialty Stores
- Sector
- CSTL Health Care
- AMRK Industrials
- Exchange
- CSTL Nasdaq
- AMRK Nasdaq
- Market Cap
- CSTL 456.2M
- AMRK 524.3M
- IPO Year
- CSTL 2019
- AMRK N/A
- Fundamental
- Price
- CSTL $20.30
- AMRK $22.80
- Analyst Decision
- CSTL Strong Buy
- AMRK Buy
- Analyst Count
- CSTL 6
- AMRK 3
- Target Price
- CSTL $37.67
- AMRK $33.00
- AVG Volume (30 Days)
- CSTL 451.0K
- AMRK 255.2K
- Earning Date
- CSTL 08-04-2025
- AMRK 08-28-2025
- Dividend Yield
- CSTL N/A
- AMRK 3.50%
- EPS Growth
- CSTL N/A
- AMRK N/A
- EPS
- CSTL N/A
- AMRK 1.57
- Revenue
- CSTL $347,083,000.00
- AMRK $10,991,521,000.00
- Revenue This Year
- CSTL N/A
- AMRK $19.62
- Revenue Next Year
- CSTL $1.36
- AMRK $2.80
- P/E Ratio
- CSTL N/A
- AMRK $14.55
- Revenue Growth
- CSTL 38.43
- AMRK 6.78
- 52 Week Low
- CSTL $15.45
- AMRK $19.39
- 52 Week High
- CSTL $35.84
- AMRK $47.39
- Technical
- Relative Strength Index (RSI)
- CSTL 66.24
- AMRK 57.85
- Support Level
- CSTL $18.18
- AMRK $21.15
- Resistance Level
- CSTL $20.63
- AMRK $23.12
- Average True Range (ATR)
- CSTL 0.78
- AMRK 0.83
- MACD
- CSTL 0.15
- AMRK 0.21
- Stochastic Oscillator
- CSTL 87.97
- AMRK 78.88
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.
About AMRK A-Mark Precious Metals Inc.
A-Mark Precious Metals Inc is a precious metal trading company. It is principally engaged in the wholesale of gold, silver, platinum, copper, and palladium bullion and related products in the form of bars, wafers, coins, and grains. The company's operating segment includes Wholesale Sales and Ancillary Services; Secured Lending and Direct-to-Consumer. It generates maximum revenue from the Wholesale Trading and Ancillary Services segment. The Wholesale Trading and Ancillary Services segment comprises business units such as Industrial, Coin and Bar, Trading and Finance, Storage, Logistics, and Mint. Geographically, it derives a majority of its revenue from the United States and the rest from Europe, Asia Pacific, Australia, Africa, and other regions.